UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Investigational new drugs, 2011-10, Vol.29 (5), p.1029-1037

2011

Volltextzugriff (PDF)

Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches

Journal of thoracic oncology, 2012-02, Vol.7 (2), p.306-315

2012

Volltextzugriff (PDF)

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

Theranostics, 2011-01, Vol.1 (1), p.290-301

2011

Volltextzugriff (PDF)

Preclinical Evaluation of the Pharmacodynamic Properties of 2,5-Diaziridinyl-3-Hydroxymethyl-6-Methyl-1,4-Benzoquinone

Clinical cancer research, 2005-04, Vol.11 (7), p.2695-2701

2005

Volltextzugriff (PDF)

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

Breast cancer research and treatment, 2010-04, Vol.120 (2), p.461-467

2010

Volltextzugriff (PDF)

Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors

Clinical cancer research, 2003-06, Vol.9 (6), p.2040-2048

2003

Volltextzugriff (PDF)

Dual repair modulation reverses Temozolomide resistance in vitro

Molecular cancer therapeutics, 2004-02, Vol.3 (2), p.123-127

2004

Volltextzugriff (PDF)

Biomarkers of cell death applicable to early clinical trials

Experimental cell research, 2012-07, Vol.318 (11), p.1252-1259

2012

Volltextzugriff (PDF)

EGFR T790M mutation testing within the osimertinib AURA Phase I study

Lung cancer (Amsterdam, Netherlands), 2017-07, Vol.109, p.9-13

2017

Volltextzugriff (PDF)

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Cancer chemotherapy and pharmacology, 2018-08, Vol.82 (2), p.285-298

2018

Volltextzugriff (PDF)

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

British journal of cancer, 2019-02, Vol.120 (4), p.379-386

2019

Volltextzugriff (PDF)

Panitumumab: A Viewpoint by Malcolm Ranson

Drugs (New York, N.Y.), 2006-01, Vol.66 (15), p.2015-2016

Ranson, Malcolm

2006

Volltextzugriff (PDF)

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

The Journal of molecular diagnostics : JMD, 2014-05, Vol.16 (3), p.343-349

2014

Volltextzugriff (PDF)

Phase II Study of Oral Topotecan in Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2000-03, Vol.6 (3), p.868

2000

Volltextzugriff (PDF)

Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer

Annals of the New York Academy of Sciences, 2008-08, Vol.1137 (1), p.98-107

2008

Volltextzugriff (PDF)

Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

Clinical cancer research, 2006-03, Vol.12 (5), p.1577-1584

2006

Volltextzugriff (PDF)

Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase

Molecular cancer therapeutics, 2004-10, Vol.3 (10), p.1215

2004

Volltextzugriff (PDF)

Randomized Trial of Paclitaxel Plus Supportive Care Versus Supportive Care for Patients With Advanced Non-Small-Cell Lung Cancer

JNCI : Journal of the National Cancer Institute, 2000-07, Vol.92 (13), p.1074-1080

2000

Volltextzugriff (PDF)

A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors

Clinical cancer research, 2014-12, Vol.20 (24), p.6284-6294

2014

Volltextzugriff (PDF)

Lomeguatrib, a Potent Inhibitor of O 6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

Clinical cancer research, 2006-03, Vol.12 (5), p.1577-1584

2006

Volltextzugriff (PDF)

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

European journal of cancer (1990), 2016-11, Vol.68, p.1-10

2016

Volltextzugriff (PDF)

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

Clinical pharmacokinetics, 2005-01, Vol.44 (10), p.1067-1081

2005

Volltextzugriff (PDF)

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

JNCI : Journal of the National Cancer Institute, 2002-10, Vol.94 (19), p.1484-1493

2002

Volltextzugriff (PDF)

Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2524-2524

2016

Volltextzugriff (PDF)

Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2513-2513

2016

Volltextzugriff (PDF)

26 – 50 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(103)

Publikationsform

Artikel
(106)
Dissertationen
(1)

Sprache

Englisch
(104)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(69)
Life Sciences & Biomedicine
(68)
Humans
(66)
Oncology
(50)
Female
(44)
Male
(39)
Middle Aged
(39)
Aged
(36)
Adult
(33)
Biological And Medical Sciences
(29)
Medical Sciences
(29)
Lung Neoplasms - Drug Therapy
(22)
Antineoplastic Agents - Therapeutic Use
(21)
Pharmacology. Drug Treatments
(19)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(16)
Lung Neoplasms - Pathology
(16)
Antineoplastic Agents
(15)
Dose-Response Relationship, Drug
(15)
Neoplasms - Drug Therapy
(15)
Treatment Outcome
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

Preclinical Evaluation of the Pharmacodynamic Properties of 2,5-Diaziridinyl-3-Hydroxymethyl-6-Methyl-1,4-Benzoquinone

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors

Dual repair modulation reverses Temozolomide resistance in vitro

Biomarkers of cell death applicable to early clinical trials

EGFR T790M mutation testing within the osimertinib AURA Phase I study

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

Panitumumab: A Viewpoint by Malcolm Ranson

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Phase II Study of Oral Topotecan in Advanced Non-Small Cell Lung Cancer

Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer

Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase

Randomized Trial of Paclitaxel Plus Supportive Care Versus Supportive Care for Patients With Advanced Non-Small-Cell Lung Cancer

A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors

Lomeguatrib, a Potent Inhibitor of O 6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors

Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792)

Suchergebnisse filtern